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ABSTRACT 
Radiofrequency ablation therapy (RFA) is a radical treatment for liver cancers and 
induces tumor antigen-specific immune responses. In the present study, we examined 
the antitumor effects of focal OK-432-stimulated dendritic cell (DC) transfer combined 
with RFA, and analyzed the functional mechanisms involved using a murine model. 
C57BL/6 mice were injected subcutaneously with colon cancer cells (MC38) in their 
bilateral flanks. After the establishment of tumors, the subcutaneous tumor on one flank 
was treated using RFA and then OK-432-stimulated DCs were injected locally. The 
antitumor effect of the treatment was evaluated by measuring the size of the tumor on 
the opposite flank, and the immunological responses were assessed using 
tumor-infiltrating lymphocytes, splenocytes and draining lymph nodes. Tumor growth 
was strongly inhibited in mice that exhibited efficient DC migration after RFA and 
OK-432 stimulated DC transfer, as compared with mice treated with RFA alone or 
treatment involving immature DC transfer. We also demonstrated that the antitumor 
effect of this treatment depended on both CD8-positive and CD4-positive cells. On the 
basis of our findings, we believe that combination therapy for metastatic liver cancer 
consisting of OK-432-stimulated DCs in combination with RFA can proceed to clinical 
trials; and it is anticipated to be markedly superior to RFA single therapy. 
 
Keywords: metastatic liver cancer, MC38, immunotherapy, intratumoral injection, 
tumor-infiltrating lymphocyte  
 
Précis: Combination therapy involving OK-432-stimulated DC transfer and 
radiofrequency ablation therapy generates augmented tumor-specific immune responses 
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in a murine metastatic colon cancer model. 
 
Abbreviations: RFA, radiofrequency ablation; DC, dendritic cell; HCC, hepatocellular 
carcinoma; TAE, transcatheter hepatic arterial embolization; TLR, Toll-like receptor; 
GFP, green fluorescent protein; ELISPOT, enzyme-linked immunospot; Treg, 
regulatory T-cell; MDSC, myeloid-derived suppressor cell; IFN-γ, interferon-γ 
  




Liver is one of the most common organs to which various cancers spread from their site 
of origin. In some types of cancer, the liver metastasis lesion is a target of surgical 
treatment. For instance, surgical resection of hepatic metastasis achieves longer median 
survival in colorectal and breast cancer patients [1,2]. However, even if the hepatic 
lesions are surgically treated, the prognosis of the patients is not satisfactory. As for 
colorectal cancers, the recurrence rate is over 50% after radical resection of metastatic 
lesions [3]. Moreover, at the time of initial diagnosis, only a few patients meet the 
criteria for hepatic resection because of unresectability, low hepatic functional reserve 
or poor performance status [4]. 
Radiofrequency ablation therapy (RFA) has been developed as a radical and 
minimally invasive treatment method for metastatic liver cancers. Recently, RFA has 
been used as an adjunct to hepatic resection, or as an alternative method to resection 
when surgical treatment is not feasible [5]. Additionally, it has been revealed that RFA 
for metastatic liver cancers generates tumor antigen-specific T-cell responses in man 
[6,7]. We have previously reported that RFA could also control distant tumor growth in 
a murine hepatocellular carcinoma (HCC) model [8].  
Dendritic cells (DCs) are potent antigen-presenting cells [9]. Recently, we have 
established new treatments using local DC injection with transcatheter hepatic arterial 
embolization (TAE), and have shown that this combination therapy could induce tumor 
antigen-specific T-cell responses in HCC patients [10]. 
OK-432 is derived from the Su strain of Group A Streptococcus pyogenes by means 
of treatment with benzylpenicillin and heat [11]. OK-432 can stimulate DCs via 
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Toll-like receptor (TLR) 3, TLR4 and β2 integrin, and subsequently induce 
antigen-specific cytotoxic lymphocytes [12-14].  
On the basis of these results, we hypothesized that OK-432-stimulated DC transfer is 
a promising candidate for an enhancer that can strongly increase the antitumor effect of 
RFA. We have previously demonstrated in a clinical trial that the local infusion of 
OK-432 by means of TAE stimulated DC levels in HCC, and could prolong 
recurrence-free survival [15]. However, it remains unknown as to how the transferred 
DCs work in combination with RFA. In the present study, we examined the antitumor 
effects of OK-432-stimulated DCs when combined with RFA, and analyzed the 
functional mechanisms involved using a murine subcutaneous colon cancer model.  
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MATERIALS AND METHODS 
 
Animals  
Wild-type 8–12 week old female C57BL/6J mice were obtained from Charles River 
Japan (Yokohama, Japan). Female C57BL/6-Tg (UBC-GFP) 30Scha/J mice were 
purchased from the Jackson Laboratory (Bar Harbor, ME, USA). All animal 
experiments were approved and performed in accordance with the Guidelines for the 
Care and Use of Laboratory Animals of Kanazawa University, which strictly conforms 
to the Guide for the Care and Use of Laboratory Animals published by the US National 
Institutes of Health.  
 
Cell lines and bone marrow-derived dendritic cells  
A murine colorectal cancer cell line, MC38 and hybridomas, clone GK1.5 and clone 
2.43 were cultured in RPMI-1640 containing 10% fetal bovine serum (Life 
Technologies, Co., Carlsbad, CA, USA) supplemented with 100 µg/mL streptomycin 
and 100 units/ml penicillin (Wako Pure Chemical Industries Ltd., Osaka, Japan). Bone 
marrow-derived dendritic cells (BMDCs) were generated using 20 ng/ml of 
recombinant granulocyte macrophage colony-stimulating factor (R&D Systems, 
Minneapolis, MN, USA) as previously described [16]. OK-432 (Picibanil; Chugai 
Pharmaceutical Co. Ltd., Tokyo, Japan) was loaded into the supernatant from days 6–7 
of the BMDC generation period at a concentration of 5 µg/ml. 
 
In vitro evaluation of phagocytic activity by dendritic cells 
MC38 cells were labeled with DiD dye (Life Technologies) according to the 
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manufacturer’s instructions followed by heat treatment at 80°C for 90 seconds. 
OK-432-stimulated or immature DCs were co-incubated with the treated MC38 cells for 
3 hours at a ratio of 1:1. After incubation, the cell suspensions were observed using a 
fluorescence microscope (BZ9000: Keyence, Osaka, Japan) and analyzed by means of 
FACSCalibur (BD Immuno-Cytometry System, San Jose, CA, USA). 
 
Animal model  
Bilateral flanks of C57BL/6 mice were each injected subcutaneously with 1×106 MC38 
cells. Seven days after injection, after they had grown to 5–6 mm in diameter, the 
subcutaneous tumors on one flank were treated using RFA, and 1×107 immature DCs or 
1×107 OK-432-stimulated DCs were injected into the treated tumors at 24 hours after 
RFA. After this, the volume of the untreated tumor on the contralateral flank was 
evaluated over a period of 10 days. Tumor volumes were calculated using the following 
formula: tumor volume (mm3) = (longest diameter) × (shortest diameter)2 / 2. 
 
Radiofrequency ablation 
Mice bearing tumors were anesthetized with an intraperitoneal injection of pentobarbital 
(Kyoritsu Seiyaku, Tokyo, Japan), and the skin on the tumor was cut. Subsequently, an 
expandable RFA needle was inserted into the tumor, which was treated using a 
radiofrequency generator (RITA 500PA; RITA Medical Systems, Inc., Fremont, CA, 
USA). During the use of this system, the intratumor temperature was maintained at 70–
90°C, and the current was turned off when the tumor exhibited heat denaturation. 
 
Flow cytometry 
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The DCs were detected by means of staining with anti-CD11c antibodies (Life 
technologies). The lymphocytes in the draining lymph node were stained with anti-CD4 
antibodies, anti-CD8 antibodies, anti-CD11c antibodies and anti-CD69 antibodies (BD 
Bioscience, San Diego, CA, USA). The splenocytes were stained with anti-CD4 
antibodies, anti-CD8 antibodies, CD11c antibodies, anti-NK1.1 antibodies, CD45 
antibodies (BD Bioscience), anti-Gr-1 antibodies, and anti-CD11b antibodies and 
mouse regulatory T-cell staining solution (BioLegend, San Diego, CA, USA). The 
stained samples were analyzed using FACSAria II (BD Immuno-Cytometry System). 
 
Immunohistochemical assay 
The draining lymph nodes and the observed tumors were embedded in Sakura 
Tissue-Tek optimum cutting temperature compound (Sakura Finetek Japan Co., Ltd., 
Tokyo, Japan) for frozen sectioning. Tissue sections were fixed at −20°C in methanol 
for 10 minutes. The draining lymph nodes were stained using rabbit anti-GFP antibody 
(Abcam, Cambridge, UK) that were detected using an EnVision+/HRP kit (Dako, 
Glostrup, Denmark). The observed tumors were stained with anti-CD4 and anti-CD8a 
(BD Bioscience), which were detected using the Nichirei Histofine Simple Stain Mouse 
Max PO (Rat) system (Nichirei Co., Tokyo, Japan) or the Vectastain ABC kit (Vector 
Laboratory, Inc., Burlingame, CA, USA).  
 
Interferon gamma enzyme-linked immunospot assay 
The splenocytes, the tumor-infiltrating lymphocytes (TILs) in the untreated tumors that 
were isolated by mechanical homogenizations and density gradient centrifugations, and 
the lymphocytes in the draining lymph nodes were loaded into the interferon gamma 
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enzyme-linked immunospot assay to estimate the tumor-specific immune reactions, as 
previously described [8,17]. Briefly, 3×105 lymphocytes or 1×105 TILs were incubated 
for 24 hours with or without 6×105 MC38 lysates, which were prepared through five 
cycles of rapid freezing in liquid nitrogen, thawing at 55°C and centrifugation. The 
number of MC38-specific IFN-γ spots was determined by subtracting the number of 
spots incubated without MC38 lysates from the number of spots incubated with MC38 
lysates. For CD4 or CD8 depletion, we used magnetic CD4-beads or CD8-beads 
(Miltenyi Biotec, Bergisch Gladbach, Germany).  
 
In vivo CD4/CD8 depletion 
For in vivo CD4 or CD8 depletion, B6 mice were injected intraperitoneally with 200 µg 
of purified monoclonal antibodies specific for CD4 or CD8 at 1 day before and 3 days 
after RFA treatment; the monoclonal antibodies were prepared from GK1.5 hybridoma 
and 2.43 hybridoma, respectively [18]. The depletion was confirmed by flow cytometry 
using peripheral blood lymphocytes stained with anti-CD4 and anti-CD8 antibodies. 
 
Statistical analysis 
The data obtained were analyzed statistically using the t test or one-way analysis of 
variance followed by Tukey’s multiple comparison test. A P value < 0.05 was 
considered as being statistically significant. 
  




Migration efficacy and phagocytic ability of OK-432-stimulated DCs 
We employed OK-432 as a modifying agent for DCs, because we have previously 
shown in clinical studies that OK-432 prolonged recurrence-free survival after 
combination therapy involving DC injection with TAE for HCC patients [10,15]. We 
first confirmed that the OK-432-stimulated murine DCs showed higher expression of 
maturation markers such as CD40, CD80, CD86, MHC class II and CCR7 
(Supplementary Fig. 1), as previously reported [19,20]. 
To evaluate their phagocytic abilities, we incubated the immature DCs and the 
OK-432-stimulated DCs with MC38 tumor cells. Heat-treated MC38 cells were taken 
up well by both immature DCs and OK-432-stimulated DCs, as compared with 
non-treated MC38 cells (Fig. 1a-c). In addition, the phagocytic ability of 
OK-432-stimulated DCs was not inferior to that of immature DCs. These results were 
consistent with the dextran uptake assay (Supplementary Fig. 2) and our previous data 
on human monocyte-derived DCs [15]. Since heat-treated MC38 cells were thought to 
be in a similar condition to those in the MC38 tumor in mice treated with RFA, 
OK-432-stimulated DCs were expected to effectively phagocytose RFA-treated MC38 
tumor cells in vivo. 
We next estimated the kinetics of the transferred DCs in mice bearing subcutaneous 
MC38 tumors treated with RFA. Immature DCs or OK-432-stimulated DCs that were 
derived from GFP-Tg mice were injected intratumorally at 24 hours after RFA 
treatment, and the subcutaneous tumors and the lymph nodes were harvested at 3 days 
after RFA. According to the immunohistochemical study involving the detection of 
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GFP, the inguinal lymph node on the RFA-treated flank was thought to be the draining 
lymph node (Supplementary Fig. 3). Additionally, the number of transferred DCs in the 
draining lymph nodes was significantly higher in the mice treated with the 
OK-432-stimulated DCs than in those treated with the immature DCs (Fig. 1d, e). Our 
experimental results attested to the fact that the OK-432-stimulated DCs had both 
sufficient phagocytic ability and higher migration efficacy. 
 
Effect of RFA in combination with the injection of OK-432-stimulated DCs on 
tumor growth 
OK-432-stimulated DCs were used in combination therapy with RFA in this murine 
model (Fig. 2a). Namely, BMDCs stimulated with OK-432 were injected into RFA 
treated tumor at 24 hours after RFA treatment. We compared four groups of tumor 
bearing mice as follows: 1) no treatment; 2) RFA only; 3) RFA with the injection of 
immature DCs; and 4) RFA with the injection of OK-432-stimulated DCs. Tumor 
volumes were measured for 10 days after treatment/no treatment. On the day after RFA, 
the treated tumors were covered with scars, started to shrink, and had disappeared 
macroscopically at 4 days after RFA in all of the groups. This indicated that RFA 
treatment was highly effective for focal lesions. The injected DCs were detected in the 
treated tumors (Supplementary Fig. 3). With regard to the untreated tumors, as we 
previously reported, the group treated with RFA only showed an antitumor effect 
against distant tumors. The injection of immature DCs combined with RFA did not 
show any additional enhancement of the antitumor effect. On the other hand, the 
volumes of the untreated tumors in the group that underwent RFA combined with the 
injection of OK-432-stimulated DCs were strongly suppressed (P<0.001) relative to 
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other groups (Fig. 2b).  
 
Recruitment of antigen-specific lymphocyte fractions in both splenocytes and 
tumor by injected OK-432-stimulated DCs  
Ten days after RFA, the tumors and the spleens were harvested and analyzed using 
immunohistochemical staining. We examined the number of tumor-infiltrating 
CD4-positive or CD8-positive cells in the tumors by means of immunohistochemistry. 
The infiltration of these cells into the untreated tumors was found to be promoted by 
RFA. The injection of OK-432-stimulated DCs after RFA induced the additional 
recruitment of CD8-positive cells into the untreated tumors (Fig. 3a, b). CD11c-, 
CD11b- and NK1.1-positive cells were very marginal and showed no differences in 
number among the four groups (data not shown).  
Systemically, in terms of analyzing splenocytes with flow cytometry, the numbers of 
CD4-positive and CD8-positive cells increased in the group treated with RFA in 
combination with OK-432-stimulated DCs. On the other hand, the CD11c and NK1.1 
fractions, which were considered as DCs and NK cells, respectively, presented no 
difference among the four groups (Fig. 3c). In addition, we examined the effect of the 
injection of OK-432-stimulated DCs after RFA on inhibitory blood cells such as 
regulatory T-cells (Tregs) and myeloid-derived suppressor cells (MDSCs) (Fig. 3c). 
Among CD4-positive cells, significantly fewer Tregs were detected in the group treated 
with RFA in combination with OK-432-stimulated DCs than in the group treated with 
RFA in combination with immature DCs. In the analysis of MDSCs, their rates of 
occurrence were not affected by treatment with either RFA alone or RFA in 
combination with DCs. Taking these results together, we concluded that treatment with 
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RFA combined with OK-432-stimulated DCs enhanced the number of CD4- or 
CD8-positive T cells and reduced the Treg/CD4 ratio, but did not influence MDSC 
numbers. 
Furthermore, we examined the number of tumor-specific IFN-γ-producing cells at 10 
days after RFA using the ELISPOT assay. The number of IFN-γ-producing cells among 
splenocytes and TILs showed the same trend as the level of tumor growth control 
among the four groups (Fig. 3d); the group treated with RFA in combination with 
injected OK-432 DCs showed the most abundant specific spots. These results suggested 
that the augmented antitumor effects of RFA combined with OK-432-stimulated DCs 
depended in large part on tumor-specific immune responses by CD4 cells or CD8 cells. 
  
Evaluation of tumor-specific immune responses in the draining lymph node after 
OK-432-stimulated DC transfer 
CD4 T- and CD8 T-cells are now thought to have an important antitumor effect as a 
result of the OK-432-stimulated DC transfer. To elucidate the priming of the 
antigen-specific immune response, we analyzed the draining lymph nodes at 3 days 
after RFA focusing on CD4-positive or CD8-positive cells. CD69, the early activation 
marker, on CD4-positive and CD8-positive cells were examined and compared between 
the immature DC transfer group and the OK-432-stimulated DC transfer group. It was 
found that CD69 expression on both CD4-positive and CD8-positive cells were elevated 
in the OK-432-stimulated DC transfer group (Fig. 4a, b). The activations were also 
demonstrated to be tumor-specific using the IFN-γ ELISPOT assay in which each 
CD4-negative and CD8-negative fraction was applied to the assay and both showed 
tumor-specific IFN-γ secretions (Fig. 4c). 
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Evaluation of the relationship between CD4-positive and CD8-positive cells and 
the antitumor effects of RFA and OK-432-stimulated DC transfer  
We have demonstrated that combination therapy involving RFA and OK-432-stimulated 
DC transfer might generate enhanced antitumor effects via tumor-specific CD4-positive 
and CD8-positive cells. To obtain further evidence, we carried out in vivo CD4 or CD8 
depletion studies in mice. Initially, we confirmed CD4 or CD8 depletion in the control 
in vivo study (Supplementary Fig. 4). The CD4-positive and CD8-positive fractions in 
the peripheral blood were greatly depleted at 7 days after injection of the antibodies. 
The experimental schedule was determined as follows. The depletion antibodies were 
injected at 1 day before and 3 days after RFA, and the tumors that were not treated with 
RFA were observed for 10 days. In addition, the draining lymph nodes were harvested 
at 3 days after RFA and analyzed (Supplementary Fig. 5). The antitumor effects of RFA 
treatment and the augmented effects from OK-432-stimulated DCs were cancelled out 
by depletion of both CD4 and CD8 cells (Fig. 5a). In the CD4 depletion study, there 
was no priming of the antitumor effect in the draining lymph nodes (Fig. 5b; 
Supplementary Fig. 6). On the other hand, in the CD8 depletion study CD4 cells were 
activated with tumor-specificities in the draining lymph node in both groups, and the 
activation was stronger in the OK-432 stimulated DC transfer group (Fig. 5b; 
Supplementary Fig. 6). Tumor-specific reactions were also demonstrated in the 
splenocytes and the TILs at 10 days after RFA. There was a tendency for OK-432 DC 
transfer treatment to result in the recruitment of increased numbers of tumor-specific 
lymphocytes into the tumor on the opposite flank (P=0.184; Fig. 5c). These results 
indicated that the tumor-specific activation of CD8 cells was necessary for the 
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antitumor effect, and was completely dependent on help from the CD4 cells. 
   




In the past decade, cytotoxic agents and molecular-targeted therapies have been 
developed, and the treatment outcomes for various cancers have improved. However, 
few patients with advanced cancers have been completely cured and thus new strategies 
for anticancer therapy are required. Immunotherapy is considered to have the potential 
to effectively treat such advanced cancers, and many different approaches have been 
explored. For the utilization of the adoptive immune response in a cancer therapy, DCs 
are a key constituent of the immune system. This is because of their natural potential to 
present tumor-associated antigens to CD4+ and CD8+ lymphocytes, and also to control 
both immune tolerance and immunity [21]. Thus, DCs are considered as an important 
target for cancer immunotherapy. Many trials and studies have been carried out 
regarding immunotherapy for cancer using DCs, some of which have been reported to 
have pronounced effects [22-25]. In recent studies, it has been revealed that RFA 
treatment induces tumor-specific T-cell responses, which is known as the abscopal 
effect; this has been mainly reported in radiotherapy studies and is augmented with 
combined immunotherapies [26,27]. Brok et al. have previously reported on the 
vaccination effects of combination therapy involving RFA and CTLA-4 antibody [28].  
To our knowledge, this is the first study that has demonstrated using a murine 
metastatic cancer model that RFA in combination with focal DC injection could 
enhance the antitumor effects of RFA alone. Our results showed that immature DCs 
made no additional immunological contribution to RFA. In the analysis of draining 
lymph nodes, few transferred DCs were detected after the injection of immature DCs. It 
appeared that immature DCs did not act as sentinels in the adoptive immune system, 
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partially because they exhibited low expression of CCR7 (the main molecule that 
promotes DC migration [29]), even though elevation of CCR7 expression using OK-432 
was very modest in our study. There is another possibility, namely that immature DCs 
are easily lysed and excluded by the host immune system [30]. On the other hand, 
mature DCs can escape cell lysis [31]. 
Utilization of OK-432-stimulated DCs improved the number of migrating transferred 
DCs in the present study. These DCs, which could act as sentinels for immunity, 
induced expansion in the number of tumor-specific lymphocytes in the draining lymph 
nodes, in the splenocytes and in the distant non-treated tumors, without systemic 
expansion of inhibitory cells such as Tregs or MDSCs. We also demonstrated that these 
augmented antitumor effects after OK-432-stimulated DC transfer were primed in the 
draining lymph nodes with tumor-specific activations of CD4-positive cells and 
CD8-positive cells; it was proved that without CD4-positive cells or CD8-positive cells, 
both the antitumor effect by RFA and the additional effect of the injection of 
OK-432-stimulated DCs disappeared completely. In addition, the in vivo CD4 depletion 
study revealed that tumor-specific activations of CD8-positive cells were not seen in the 
draining lymph nodes in both groups after the injection of immature DCs and 
OK-432-stimulated DC injection; in other words, tumor-specific CD8 activation 
depended on CD4-positive cells entirely. In the CD8 depletion study, on the other hand, 
we found that tumor-specific CD4-positive cells appeared in the draining lymph nodes, 
the splenocyte population and the untreated tumor on the opposite flank, and these 
lymphocytes were considered to be CD4 positive cells. In the tumor-infiltrating 
lymphocytes, there was a tendency for more tumor-specific CD4-positive cells to be 
recruited after treatment involving OK-432-stimulated DC transfer. Many researchers 
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have demonstrated the contribution of CD4 cells to cytotoxicity [32,33]. However, in 
our experimental models, tumor-specific CD4 positive cells were not observed to 
contribute to the antitumor effect. Summarizing the above, in our study, the 
CD4-positive cells were required for the priming of the immune responses, and the 
CD8-positive cells acted as the effector cells after help from the CD4-positive cells. 
In conclusion we consider, on the basis of our preclinical findings regarding 
combination therapy involving OK-432-stimulated DCs with RFA for the treatment of 
metastatic liver cancer that clinical trials can now proceed. It is anticipated that this 
combination therapy will be markedly superior to RFA single therapy. 
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Figure 1: Effects of OK-432 on murine bone marrow-derived DCs. (a) 
OK-432-stimulated DCs or immature DCs were co-incubated for 3 hours with MC38 
cells untreated or treated at 80°C for 90 seconds after staining with DiD dye. After 
incubation, DC and MC38 cells were observed using a fluorescence microscope. 
Arrowheads indicate MC38 derivatives being phagocytosed by DCs. No tx, untreated 
MC38 cells; Heat tx, heat-treated MC38 cells; Bar, 20µm. (b) and (c) Co-incubated 
MC38 cells and DCs were stained with anti-CD11c antibodies and analyzed using flow 
cytometry. The histograms show the DiD fluorescent intensity of the CD11c positive 
fractions. The percentages of DiD+CD11c+ cells in the CD11c+ cell population are also 
shown in a column graph. The experiments were performed five times and 
representative results are shown. Data are presented as the mean ± SE. *, P<0.05. (d) 
The migration abilities of the DCs after intratumoral transfer were evaluated. The 
draining lymph nodes were harvested at 3 days after RFA followed by the DC transfer. 
Frozen sections were prepared and stained with anti-GFP antibodies. Arrows indicate 
the GFP-positive cells in the lymph nodes. Bar, 20µm. (e) The draining lymph nodes 
were also analyzed using flow cytometry after staining with anti-CD11c antibodies. 
Data were obtained from six mice in each group. Percentages of GFP+CD11c+ cell are 
presented as the mean ± SE. **, P<0.01.  
 
Figure 2: Impact of injection of OK-432-stimulated DCs into murine MC38 
subcutaneous tumors. (a) RFA was administered to a tumor on one flank followed by 
injection of 1×107 DCs into the treated tumor. The untreated tumor on the opposite 
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flank was observed for 10 days. The solid arrowheads indicate the treatment 
intervention sites and the open arrowhead indicates the observed untreated tumor. (b) 
The tumor volumes were compared among the four groups as follows: 1) no treatment; 
2) RFA only; 3) RFA in combination with immature DC injection; and 4) RFA in 
combination with OK-432-stimulated DC injection. n=8 mice per group. The data are 
presented as the mean ± SE. *, P<0.05; **, P<0.001. 
 
Figure 3: Analysis of the tumor-infiltrating lymphocytes and the splenocytes after 
combination therapy with RFA and DC injection. (a) CD4-positive and CD8-positive 
cells in the observed untreated tumors were detected using immunohistochemistry at 10 
days after RFA. The black bar represents 50 µm. (b) The number of positive cells was 
counted using a microscope. This was achieved by counting the number of cells in six 
randomly chosen tumor areas at 400-fold magnification. Three mice were used in each 
group. The data are presented as the mean ± SE. ***, P<0.001; ns, not significant. (c) 
Ten days after RFA, splenocytes were stained with anti-CD4, anti-CD8, anti-NK1.1 and 
anti-CD11c antibodies and analyzed using flow cytometry. Regulatory T cells (Tregs) 
defined as CD4+CD25+Foxp3+ cells and myeloid-derived suppressor cells (MDSCs) 
defined as CD11b+Gr-1+ cells were counted and compared among the four groups. Six 
mice were analyzed in each group. The data are presented as the mean ± SE. *, P<0.05; 
**, P<0.01; ***, P<0.001; ns, not significant. (d) Immune responses by the splenocytes 
and the tumor-infiltrating lymphocytes (TILs) were examined by means of the IFN-γ 
enzyme-linked immunospot (ELISPOT) assay using MC38 lysate. In the assay for TILs, 
1×105 TILs were mixed with 2×105 splenocytes from B6 mice and applied to the well. 
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Six mice were analyzed in each group. The data are presented as the mean ± SE. **, 
P<0.01; ***, P<0.001; ns, not significant. 
 
Figure 4: Antigen-specific activation of both CD4-positive and CD8-positive cells in 
the draining lymph node. (a) Three days after RFA followed by DC transfer the draining 
lymph node was harvested and analyzed by staining with anti-CD4 antibodies, anti-CD8 
antibodies and anti-CD69 antibodies. The fluorescence intensities of CD69 in the 
CD4-positive and CD8-positive fractions are compared between the OK-432-stimulated 
DC transfer group and the immature DC transfer group. The data were obtained from 
six mice in each group. The histograms show the representative data. (b) The mean 
fluorescent intensities are also presented as the mean ± SE. *, P<0.05. (c) The 
antigen-specificities of the T-cell activations were confirmed by means of the IFN-γ 
ELISPOT assay using MC38 lysate. After CD4 or CD8 depletion using CD4 and CD8 
magnetic beads, the lymphocytes from the draining lymph nodes were submitted to 
IFN-γ ELISPOT assay. Data were obtained from six mice in each group. *, P<0.05; **, 
P<0.01. 
 
Figure 5: The augmented antitumor effects depended on both CD4-positive and 
CD8-positive cells. (a) For in vivo CD4 or CD8 depletion, monoclonal antibodies 
specific for CD4 (GK1.5) or CD8 (2.43), respectively, were injected intraperitoneally at 
1 day before and 3 days after RFA. Tumor volumes were compared among the four 
groups for 10 days after RFA. In each experiment, data were obtained from four mice 
per group and are presented as the means ± SE. ns, not significant. (b) The draining 
lymph nodes were harvested at 3 days after RFA and analyzed for their 
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tumor-specificities using the IFN-γ ELISPOT assay. Two mice were used in each group. 
Data are shown as the mean ± SE. *, P<0.005; ns, not significant. (c) In the CD8 
depletion study, splenocytes and tumor-infiltrating lymphocytes (TILs) were evaluated 
for their tumor-specificities using the IFN-γ ELISPOT assay as described in Fig. 3. Four 
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